ReviewTranslational cancer research2025
Recent advances in development of CDK7 inhibitors and their clinical trials: a narrative review.
Review in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Optimization of 3D Spheroid Models of Ovarian, Breast, and Gastric Cancer for Comparative Screening of Drug Candidates.ACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: CDK7, a member of the CDK-activating kinase (CAK) family, plays a key role in cell cycle, transcriptional regulation and in regulating the proliferation and apoptosis of tumor cells. Some evidence suggests that CDK7 is a promising target for cancer treatments, so it is of great significance to develop an efficient and highly selective CDK7 inhibitor. CDK7 inhibitors have not yet been marketed. This review focuses on some selective CDK7 inhibitors currently in clinical research, and introduces their targets, indications, and the latest clinical trial progress in detail. Methods: We investigated the recent advances in development of CDK7 inhibitors and their clinical trials from online website (Google Scholar, ClinicalTrials.gov) and electronic databases [PubMed, CDDI (Cortellis Drug Discovery Intelligence)]. Key Content and Findings: CDK7, as an important pathway key node, is involved in the regulation and transcription of the cell cycle, and is highly expressed in a variety of tumor cells, which is a good biomarker. In addition, CDK7 plays a key role in regulating the proliferation and apoptosis of tumor cells. By selectively inhibiting CDK7 activity in tumor tissues, it can play a positive role in tumor treatment. Compared with the first-generation pan-CDK7 inhibitors, the second-generation selective CDK7 inhibitors have more potent activity, better selectivity and druggability. Selective CDK7 inhibitors currently under investigation are mainly divided into two categories: (I) selective covalent CDK7 inhibitors and (II) selective non-covalent CDK7 inhibitors. This review summarizes the recent findings on selective CDK7 inhibitors, with a focus on their indications, and the latest clinical trial progress. Conclusions: Overall, CDK7 is a very promising anti-tumor target for the treatment of breast cancer, solid tumors, ovarian cancer and triple negative breast cancer (TNBC), etc. There is no doubt about that, however, its specific inhibitors still need to be developed with scientists' tireless efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.